Key terms
About FENC
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FENC news
May 17
10:01am ET
Biotech Alert: Searches spiking for these stocks today
May 16
3:40pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
May 16
10:45am ET
Biotech Alert: Searches spiking for these stocks today
May 15
8:57am ET
Fennec price target lowered to $17 from $20 at Craig-Hallum
May 15
8:25am ET
Fennec Pharmaceuticals: Temporary Setbacks with Strong Long-Term Outlook
May 15
6:36am ET
Maintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic Partnerships
May 15
6:16am ET
Fennec price target lowered to $15 from $18 at H.C. Wainwright
May 14
7:37pm ET
Fennec Pharmaceuticals Sees Robust Q1 Growth
May 14
9:47am ET
Fennec Pharmaceuticals trading resumes
May 14
9:32am ET
Fennec Pharmaceuticals trading halted, volatility trading pause
May 14
9:10am ET
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)
May 14
6:05am ET
Fennec reports Q1 EPS 41c, consensus 26c
May 06
2:25am ET
Fennec Pharmaceuticals (FENC) Gets a Buy from Capital One Financial
Apr 04
6:26am ET
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
Apr 04
6:11am ET
Fennec price target raised to $18 from $17 at H.C. Wainwright
Apr 01
2:37pm ET
Fennec Pharmaceuticals Reports Strong 2023 Growth
Mar 29
7:35am ET
Fennec Pharmaceuticals: A Strong Buy on PEDMARK’s Success and Expansion Potential
Mar 27
11:25am ET
Fennec participates in a conference call with Craig-Hallum
Mar 27
4:55am ET
Fennec participates in a conference call with Craig-Hallum
Mar 22
1:50pm ET
Fennec participates in a conference call with Craig-Hallum
Mar 22
9:38am ET
Fennec price target raised to $20 from $18 at Craig-Hallum
Mar 21
8:45pm ET
Buy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potential
Mar 21
7:37pm ET
Fennec Pharmaceuticals Files SEC 8-K Report
Mar 21
6:37am ET
Fennec Pharmaceuticals’ Soaring Sales and New Deal
Mar 21
6:03am ET
Fennec reports Q4 EPS (10c), consensus (2c)
Mar 18
3:05pm ET
Fennec price target raised to $18 from $17 at Craig-Hallum
Mar 18
12:35pm ET
Capital One Financial Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
Mar 17
9:37pm ET
Fennec Pharmaceuticals Strikes Major European Deal
Feb 29
12:25pm ET
Buy Rating for Fennec Pharmaceuticals Amid Strong Pedmark Sales and Market Expansion Potential
Feb 29
9:25am ET
Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
Feb 29
7:16am ET
Fennec sees FY23 revenue $20.7M-$21.2M, consensus $19.57M
No recent press releases are available for FENC
FENC Financials
Key terms
Ad Feedback
FENC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FENC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range